Danaher Corporation (DHR)
NYSE · Washington, D.C., USA · Founded 1969 · CEO Julie Sawyer Montgomery
Valuation summary
$159.04 fair value versus $227.56 in the market, a difference of -30.1%. Rated Sell.
| Fair value per share | $159.04 |
| Current share price | $227.56 |
| Upside / downside | -30.1% |
| Bear case | $102.28 |
| Bull case | $238.73 |
| Discount rate (WACC) | 8.9% |
| Terminal growth | 2.60% |
| Market capitalisation | $160B |
| EV / Sales | 7.1x |
About Danaher Corporation
Founded in 1969 as a real estate trust and rebuilt as an industrial conglomerate by the Rales brothers. Rainer Blair, CEO from 2020, handed over on 1 October 2026 to Julie Sawyer Montgomery, who joined Danaher in 2017. Danaher has spent the last decade transforming itself into a pure life sciences and diagnostics company, spinning off its industrial businesses as Fortive and Veralto. The Danaher Business System — a rigorous continuous-improvement methodology applied to every acquisition — is the operational core of the company and is widely imitated.
Investment case
- Cytiva and Pall give Danaher a leading position in bioprocessing, the equipment used to manufacture biologic drugs.
- Around 75% of revenue is recurring consumables and services.
- The Danaher Business System has a long, verifiable record of improving acquired businesses.
Key risks
- Bioprocessing demand fell sharply as customers worked through pandemic-era inventory, and the recovery has been slow.
- China is a meaningful market and remains weak.
- Valuation still reflects a premium quality rating that recent growth has not supported.
Recent developments
- 2026-10-21 · Q3 revenue up 8.5% to $6.55bn with core growth of 5.5% excluding respiratory; 2026 adjusted EPS guide raised to $8.57-$8.62 source
- 2026-10-01 · Julie Sawyer Montgomery became Danaher president and CEO, succeeding Rainer Blair, who stays as senior adviser to 31 March 2027; succession was announced 3 August 2026. source
Revenue by segment
| Biotechnology | 27% |
| Life Sciences | 30% |
| Diagnostics | 43% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $26.9B | $7.9B |
| Year 2 | $28.4B | $8.1B |
| Year 3 | $29.9B | $8.2B |
| Year 4 | $31.6B | $8.4B |
| Year 5 | $33.3B | $8.6B |
What the street says
Long regarded as one of the best-run companies in healthcare. The bear case centres on bioprocessing normalisation timing, and the October 2026 handover from Rainer Blair to Julie Sawyer Montgomery adds a leadership transition to watch.
Comparable companies: NVO · GILD · AMGN · BMY · PFE · GSK · NVS · TMO
Open the interactive model, price chart and sensitivity grid →